The new drug application contains data from the ZENITH20 trial, demonstrating the drug's activity in NSCLC patients with HER2 exon 20 insertion mutations.
Tom Riga named President and Chief Executive Officer and will join the Board of Directors effective December 31, 2021Joe Turgeon, President and Chief Executive Officer, to retire and step down from Board of DirectorsHENDERSON, Nev. (BUSINESS WIRE) Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutica.
Manufacturing Deficiencies Delay Decision on Eflapegrastim empr.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from empr.com Daily Mail and Mail on Sunday newspapers.
Why Spectrum Pharmaceuticals Stock Is Crashing Today fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
Operator
Good afternoon, ladies and gentlemen, and welcome to the Spectrum Pharmaceuticals First Quarter 2021 Earnings Conference Call. [Operator Instructions]
I would now like to turn the conference over to your host, Mr. Kurt Gustafson, Chief Financial Officer.
Kurt A. Gustafson
Executive Vice President and Chief Financial Officer
Thank you, operator, and good afternoon to everyone. Thank you for joining us today for Spectrum Pharmaceuticals first quarter 2021 financial results conference call. Our first quarter financial results press release was sent out earlier this afternoon, and is available on our website at www.sppirx.com.
Joining me on the call today from Spectrum Pharmaceuticals will be Joe Turgeon, President and CEO, and Dr. Francois Lebel, Chief Medical Officer.